Carcinomatosis peritoneal secundaria a carcinoma de mama

Abstract

The incidence of breast cancer is increasing. On the other hand, mortality has decreased in recent years. Increasing survival means that a greater number of recurrences are detected.An uncommon and late way of presentation of metastatic disease is at peritoneum. This represents a challenge in management at diagnosis and treatment, given the lack of recommendations and studies in this regard. Therefore, the objective was to carry out a bibliographic review on the latest updates on the diagnostic and therapeutic management of peritoneal carcinomatosis secondary to breast carcinoma and its survival. An exhaustive search has been carried out in different databases on the latest updates on the therapeutic management of peritoneal carcinomatosis in breast cancer. Finally, 31 articles have been included. Breast cancer is the extra-abdominal solid tumor that produces the most peritoneal carcinomatosis and the lobular subtype is the one most associated with this way of dissemination of the disease. The clinical presentation and diagnosis occur usually late, associated with a poor prognosis. The evidence regarding the ideal therapeutic management is scarce, but it has been shown that cytoreduction surgery + HIPEC (hyperthermic intraoperative chemotherapy) presents promising results in selected cases, observing improvement in survival and quality of life of affected patients. Quality prospective studies with a larger sample size are needed to determine the appropriate therapeutic management in peritoneal carcinomatosis due to breast carcinoma.